Shares of Novartis NVS decreased 1.6% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share rose 7.80% year over year to $1.52, which beat the estimate of $1.45.
Revenue of $12,259,000,000 rose by 0.71% year over year, which missed the estimate of $12,530,000,000.
Outlook
Novartis hasn't issued any earnings guidance for the time being.
Novartis hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Oct 27, 2020
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/3soac2di
Price Action
Company's 52-week high was at $99.84
52-week low: $69.18
Price action over last quarter: down 4.24%
Company Profile
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.